Generics giant Teva Pharmaceuticals (NYSE:TEVA) has named Richard Francis, the CEO of gene therapy company Purespring Therapeutics, as its leader. Purespring Therapeutics is one of the first adeno-associated virus (AAV) gene therapy companies focused on kidney disease. Francis is also the CEO of the cardiotherapy-focused firm Forcefield Therapeutics, and an operating partner for Syncona Investment…